Ilant Health, a value-based obesity treatment company that works with employers and health plans to improve clinical outcomes while reducing the total cost of care, announced that it has raised $15 million in Series A funding. The financing brings the company’s total funding to more than $22 million to date.
The round was led by Cornucopian Capital, with participation from naturalX, Peakbridge, Semcap AI, Evidenced, Operator Partners, and existing investors Celtic, LifeX, and AlphaLab.
Founded by Elina Onitskansky, whose background includes roles at McKinsey and Molina Healthcare, Ilant Health is focused on transforming obesity care from fragmented interventions into a continuous, personalized care model. The company combines clinician-led treatment with AI-enabled technology to create individualized care pathways that adapt over time based on clinical, behavioral, and personal data.
Ilant’s approach integrates behavioral therapy, medications including GLP-1 and non-GLP-1 treatments, and surgical options within a comprehensive care model that also addresses nutrition, physical activity, stress, and overall health. The company aims to optimize treatment selection and continuously refine care plans to improve outcomes while reducing unnecessary healthcare spending.
According to Ilant, early program results show members achieving an average weight loss of 15%, significantly exceeding the 5.8% weight-loss outcomes reported in real-world settings. The company also reported broader health improvements, including enhanced biometric measures and an average increase of two mentally healthy days per month.
The company has gained traction among employers and healthcare partners seeking alternatives to traditional obesity management programs that focus primarily on medication access or cost controls. Ilant’s model is designed to deliver measurable clinical outcomes alongside financial savings for employers and payers.
One example of that traction comes from SEIU 775 Benefits Group, which partnered with Ilant after the company conducted an analysis to identify members most likely to benefit clinically and financially from obesity treatment interventions.
In November 2025, Ilant expanded its market presence by announcing direct contracting and transparent pricing solutions for obesity medications through Lilly’s Employer Connect program. The company is also working with Novo Nordisk, enabling employers to gain greater visibility and control over pharmaceutical spending in one of healthcare’s fastest-growing cost categories.
The new capital will support Ilant’s continued growth as demand increases for integrated obesity and cardiometabolic care models that balance expanded treatment access with cost management and long-term outcomes.
KEY QUOTES:
“Employers and health plans are facing a real dilemma right now — they are faced with either expanding access and watching pharmaceutical costs rise dramatically, or restricting access and risking rising chronic disease and cost. That’s not a sustainable model. If we don’t change how care is delivered, we’re just paying more for the same broken system, and we risk a crisis where both chronic disease and costs are spiraling out of control. Ilant’s model focuses on delivering real value with manageable treatment costs and clinically meaningful care that actually bends the cost curve.”
Elina Onitskansky, Founder and CEO, Ilant Health
“What stood out with Ilant was their precision-based, data-driven approach to obesity care, not a one-size-fits-all model centered on medication only. Ilant conducted a detailed analysis of our population and identified the members most likely to benefit clinically and financially, giving us confidence in both improved outcomes and meaningful ROI. Just as importantly, the members consistently share positive feedback about the care, support, and personalized attention they receive from the Ilant team.”
Kenneth L. Gardner, Director of Growth, Benefit Operations, SEIU 775 Benefits Group
“We believe the next generation of category-defining companies will be those that deliver outcomes as a service, not just tools or access. Ilant is applying that model to one of the most important and costly areas in healthcare. The company understands that the future of obesity and cardiometabolic care will not be defined by access to a single class of drugs, but by the ability to deliver the right care to the right patient at the right time. Their model aligns clinical rigor with economic value in a way that we believe will define this category over the next decade.”
Aryeh Ganz, Founder and Managing Partner, Cornucopian Capital
